Effect of curcumin on rats/mice with diabetic nephropathy: a systematic review and Meta-analysis of randomized controlled trials  by Wu, Wei et al.
TOPIC
JTCM |www. journaltcm. com August 15, 2014 |Volume 34 | Issue 4 |
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2014 August 15; 34(4): 419-429
info@journaltcm.com ISSN 0255-2922
© 2014 JTCM. All rights reserved.
SYSTEMATIC REVIEW
Effect of curcumin on rats/mice with diabetic nephropathy: a sys-
tematic review andMeta-analysis of randomized controlled trials
WeiWu, Hua Geng, Zhaoru Liu, Hong Li, Zhangzhi Zhu
aa
Wei Wu, Hua Geng, Zhaoru Liu, Hong Li, Institute of Dia-
betes, the First Clinical Medical College of Guangzhou Uni-
versity of Traditional Chinese Medicine, Guangzhou 510405,
China
Zhangzhi Zhu, Department of Endocrine, the First Affiliated
Hospital of Guangzhou University of Traditional Chinese
Medicine, Guangzhou 510405, China
Correspondence to: Prof. Wei Wu, Institute of Diabetes,
the First Clinical Medical College of Guangzhou University
of Traditional Chinese Medicine, Guangzhou 510405, China.
wuwei.jiujiang@163.com
Telephone: +86-20-36587241; +86-13711280371
Accepted: September 3, 2013
Abstract
OBJECTIVE: To assess the renal protective effects
of curcumin administration on diabetic rats/mice.
METHODS: Databases were searched electronically
and conference papers searched manually for
search terms to find relevant studies. Articles were
assessed independently by two reviewers. Re-
view Manager 5.1 was used for data analysis.
RESULTS: Fourteen randomized controlled experi-
ments were included. Meta-analysis demonstrated
that blood sugar levels and kidney weight to body
weight ratios in the model group were higher than
those in the normal group, and the curcumin
group had significantly lower mesangial area to glo-
merular area ratios compared with the model
group, and also lower levels of urinary protein,
blood urea nitrogen and serum creatinine.
CONCLUSION: Curcumin shows protective effects
on the kidneys of rats/mice with diabetes.
© 2014 JTCM. All rights reserved.
Key words: Curcumin; Diabetic nephropathies; Me-
ta-analysis; Review; Randomized controlled trials
INTRODUCTION
Diabetic nephropathy (DN) is not only one of the
most common complications of diabetes, but also one
of the main causes of death from diabetes.1 With the
average lifespan increasing globally, DN has become a
worldwide problem, and seriously threatens human
health.2,3 In developed countries in Europe and Ameri-
ca, DN is a leading cause of end stage renal disease
(ESRD).4 In China, DN accounts for about 15% of
ESRD, and DN will be a leading cause of ESRD in the
21st century.5,6 Unfortunately, the pathogenesis of DN
is not yet fully understood. Basic treatment includes
controlling blood sugar and blood pressure levels, but
there are no effective measures to reverse, arrest or even
delay the progression of DN. Some DN patients gradu-
ally develop ESRD.7 Traditional Chinese Medicine at-
tempts to treat and control diabetes and its complica-
tions by preserving islet beta-cells, increasing serum in-
sulin levels8 and insulin sensitivity,9 and improving in-
sulin sensitivity.10 Animal experiments, to some extent,
may give insights into the mechanisms of DN, but a
single study may not fully reveal all the details. A sys-
tematic review may provide more significant evalua-
tion of the effects. Although many studies globally
have reported that curcumin is able to lower blood glu-
cose levels, improve blood lipid metabolism, and slow
down the progression of DN in diabetic rats/mice, it is
still necessary to evaluate the effects of curcumin ad-
ministration with a systematic review to provide more
significant information about the experimental results.
METHODS
Database search strategy
The following electronic databases were searched:
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PubMed (Jan 1966 to May 2013), EMBASE (Jan
1966 to May 2013), China National Knowledge Infra-
structure Database (CNKI) (Jan 1979 to May 2013),
Chinese Biomedical Literature Database (CBM) (Jan
1979 to May 2012), Wanfang Database (Jan 1980 to
May 2013), China Science and Technology Journal
Database (VIP) (Jan 1989 to May 2013). Additionally,
important conference papers were searched manually.
The search terms used were: "rats", "mice", "animal
models", "experiment", "diabetes" or "diabetic ne-
phropathy" combined with "curcumin". All articles
were written in either English or Chinese. The searches
were carried out independently by two reviewers (Wei
Wu and Hua Geng who studied the evidence-based
medicine courses of Guangzhou University of Tradi-
tional Chinese Medicine and passed the test).
Exclusion criteria
Exclusion criteria were: (a) clinical trials; (b) cell experi-
ments; (c) studies of non-diabetic models; (d) studies
with incomplete data, statistical mistakes, and/or differ-
ent basic treatments between groups; and (e) repeated
and similar studies.
Data extraction and quality assessment
The two reviewers independently extracted data from
each article. Discrepancies were resolved by discussion
or with the assistance of a third reviewer (Zhaoru Liu,
studied the evidence-based medicine courses of Guang-
zhou University of Traditional Chinese Medicine and
passed the test). The following information from each
article was taken: article title, name of first author, year
published and location, experimental environment, ani-
mal and model features, sample size, experimental de-
sign, drug dosage and administration, the number of
animals excluded and the reasons, the number of dead
animals, and outcomes (blood sugar, urinary protein,
and serum creatinine levels). The quality of each study
was assessed using items described in the ARRIVE
guidelines (animal research: reporting in vivo experi-
ments), which are recommended for quality assessment
of animal experiments.11,12 These items are based on the
presence and short description of important study char-
acteristics, such as title, abstract, background, objec-
tives, ethical statement, study design, experimental pro-
cedures, experimental animals, housing and husband-
ry, sample size, allocating animals to experimental
groups, experimental outcomes, statistical methods,
baseline data, numbers analyzed, outcomes and estima-
tion, adverse events, interpretation/scientific implica-
tions, generalizability/translation, and funding.
Data synthesis and analysis
We synthesized the results with Meta-analysis using Re-
view Manager software (version 5.1;13 Nordic Co-
chrane Center, Copenhagen, Denmark). Dichotomous
data are presented as odds ratio (OR), relative risk (RR)
or risk difference (RD); and continuous outcomes as
weighted mean difference (WMD), mean differences
(MD) or standard mean differences (SMD), both with
95% confidence intervals (CI). Heterogeneity was test-
ed using χ2 tests. Subgroup analysis was performed to
evaluate the overall effects in possible subgroups
grouped according to model type, study period, and
drug dosage. A P value of <0.05 was considered statisti-
cally significant. Bias was examined using a funnel plot.
RESULTS
Characteristics of included studies
A total of 101 studies in Chinese or English were col-
lected, and 14 articles were included in the final analy-
sis.14-27 Of the 14 articles, nine were from China,14-20,23,27
three from India,21,25,26 one from Japan,24 and one from
Thailand.22 Of the nine studies from China, eight were
published in Chinese.14-20,27 The remaining studies were
published in English.
The search steps used are shown in Figure 1. All experi-
mental animals were purchased from one laboratory an-
imal center, which including spontaneous diabetic rats/
mice and induced diabetic rats/mice. For all but one
study27 of 10-week-old spontaneous diabetic mice, a
blood glucose concentration above 16.7 mmol/L was
used as the diabetic model standard in nine studies,14-16,18-20,
22-25above13.9mmol/Linonestudy,22above11.1 mmol/L
in two studies,21,26 and strong positive urine sugar in
one study.17 Intraperitoneal injection and gavage were
used in the other studies. The dosage of curcumin was
between 50 and 250 mg·kg-1·d-1 for all 14 studies. The
duration of treatment ranged between 6 and 18 weeks.
The characteristics of the studies are shown in Figure 1.
Quality of the included trials
All studies were randomized controlled trials. There
was only one study15 that described the specific method
of randomization. In that study, animals were grouped
according to blood sugar levels and weights. All studies
reported the title, abstract, background, objectives,
study design, experimental procedures, experimental
animals, sample size, allocating animals to experimen-
tal groups, experimental outcomes, statistical methods,
baseline data, numbers analyzed, outcomes and estima-
tion, and interpretation/scientific implications. Of all
included studies, 71.43% 14,17-19,21,23-27 reported housing
and husbandry, and 28.57% 21,23-25 reported an ethical
statement. No studies reported adverse events and gen-
eralizability/translation, and 50%14,15,22-26 reported fund-
ing (Figure 2).
Treatment effects
Blood sugar levels: as shown in Figure 3, blood sugar
levels were reported in 11 studies.14,15,17-21,23-25,27 Sub-
group analysis was carried out because different animal
models were used. Blood sugar levels were significantly
higher in the model group compared with the normal
group [SMD=11.79, 95% CI (8.22, 15.35), P<0.01].
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Figure 2 Quality assessment of the included studies
Y: reported in the studies; N: not reported in the studies.
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Heterogeneity was significant in the group of studies
(heterogeneity χ2=60.57, P<0.01, I2=83% ). In addi-
tion, statistical significances were observed in sub-
groups of the spontaneous diabetic model (one study,27
P<0.01) and the induced diabetic model (10 studies,14,
15,17-21,23-25 P<0.01) (Figure 3). For the curcumin group
and the model group, a random effect model was ap-
plied as a result of heterogeneity across the studies (het-
erogeneity χ2=51.61, P<0.01, I2= 81%), and blood sug-
ar levels were observed to be significantly different be-
tween the two groups [SMD=1.26, 95% CI (0.31,
2.22), P<0.05]. A subgroup of the induced diabetic
model showed statistical significance (10 studies,14,15,17-21,
23-25 P<0.01) (Figure 4).
Kidney weight to body weight ratios
Of the 14 studies, six reported kidney weight to body
weight ratios.16,17,20,23,25,27 The model group showed a sig-
nificant increase in kidney weight to body weight ra-
tios [MD=0.38, 95% CI (0.26, 0.49), P<0.01], and
heterogeneity was high (χ2=2240.45, P<0.000 01, I2=
100% ). When subdividing by different animals mod-
els, studies involving models induced by unilateral ne-
phrectomy17 and non-nephrectomy16,20,23,25,27 were all as-
101 records identified
through electronic
database searching
0 additional records
identified
through other sources
CNKI database 14 records
CBM database 26 records
VIP Information 21 records
Wanfang database 28 records
Pubmed 12 records
Embase 12 records
39 records assessed after
72 similar and reduplicate
studies removed
19 articles assessed for eligibility
20 cells experiments
excluded according
to title or abstract
14 studies included finally
5 studies without
complete datas
excluded according to
reading the full article
Figure 1 Flow chart of search steps
CNKI: China National Knowledge Infrastructure Database; CBM: Chinese Biomedical Literature Database; VIP: China Science and
Technology Journal Database.
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sociated with significant increases in kidney weight to
body weight ratios (P<0.01) (Figure 5).
The kidney weight to body weight ratios of the cur-
cumin group were significantly lower than that of the
model group [MD=0.16, 95% CI (0.10, 0.21), P<
0.01], and heterogeneity was high (χ2=118.55, P<
0.000 01, I2=96%). Subgroup analysis showed that, in
studies involving models induced by unilateral nephrec-
tomy17 and non-nephrectomy,16,20,23,25,27 the kidney
weight to body weight ratios in the curcumin group
were significantly lower than that of the model group
(P<0.01) (Figure 6).
Urinary protein
Of the 14 studies, three reported 24-h proteinuria,14,23,24
two reported 24 h albuminuria,17,27 and five reported
urinary albumin excretion rate.16,18-21 Compared with
the model group, urinary protein levels were lower in
the curcumin group [SMD=3.99, 95% CI (2.63,
5.36), P<0.000 01]. This reduction was associated
with significant heterogeneity between the two groups
(χ2=43.29, P<0.000 01, I2=79% ). Subgroup analysis
showed a beneficial effect of curcumin for all sub-
groups (P<0.01) (Figure 7).
Figure 3 Comparison of blood sugar levels between the model group and the normal group
Figure 4 Comparison of blood sugar levels between the model group and the curcumin group
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Serum creatinine levels
As shown in Figure 8, serum creatinine levels were re-
ported in seven studies.14,16,20,21,23,24,27 Significant effects
were observed in the curcumin group compared with
the model group [SMD=3.81, 95% CI (1.93, 5.69), P<
0.01, heterogeneity χ2=41.91, P<0.000 01, I2=86%].
Blood urea nitrogen (BUN)
Of the 14 studies, seven reported that the curcumin
group showed a significant improvement in BUN lev-
els when compared with the model group.15,16,20,21,23,24,27
Meta-analysis of seven studies showed a favorable ef-
fect in the curcumin group on BUN levels compared
with the model group [SMD=2.99, 95% CI (1.14,
4.84), P<0.01]. Marked heterogeneity was observed in
this model (χ2=43.60, P<0.000 01, I2= 86% ) (Figure
9).
Triglycerides
Only two studies reported triglyceride levels in the
blood.15,24 Based on different models, subgroup analysis
was performed and the results are shown in Figure 10.
No significant difference was found between the cur-
cumin group and the model group [SMD=28.88, 95%
CI (-30.61, 88.37), P=0.34, heterogeneity χ2=11.70,
P=0.0006, I2=91% ]; whereas in the basal diet sub-
group,24 there was significant difference between the
two groups (P<0.01).
Mesangial area to glomerular area ratios
Of the 14 studies, only two reported mesangial area to
glomerular area ratios. Based on different models, sub-
group analysis was performed. Figure 11 shows the for-
est plot for mesangial area to glomerular area ratios.
The curcumin group showed significantly lower mesan-
gial area to glomerular area ratios compared with the
model group [MD=14.53, 95% CI (10.38, 18.68), P=
0.34, heterogeneity χ2=0.77, P=0.38, I2=0% ]. Signifi-
cant differences were also found in the unilateral ne-
phrectomy subgroup17 (P<0.01) and in the non-ne-
Figure 5 Comparison of kidney weight to body weight ratios between the model group and the normal group
Figure 6 Comparison of kidney weight to body weight ratios between the model group and the curcumin group
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phrectomy subgroup18 (P<0.01).
Intensity of vascular endothelial growth factor
(VEGF)
Only one study reported the intensity of VEGF in re-
nal tissues.22 There was less intensity of VEGF in renal
tissues in the curcumin group compared with the model
group.
Expression of adenosine monophosphate activated
protein kinase (AMPK)
Only one study reported the expression of AMPK in re-
nal tissues.24 Compared with the model group, the cur-
cumin group showed a beneficial effect for preventing
Figure 7 Comparison of urinary protein levels between the model group and the curcumin group
Figure 9 Comparison of BUN levels between the model group and the curcumin group
Figure 8 Comparison of serum creatinine levels between the model group and the curcumin group
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the reduction in AMPK phosphorylation.
Aldose reductase and sorbitol dehydrogenase
Only one study reported the activities of aldose reduc-
tase and sorbitol dehydrogenase in renal tissues.26 Alter-
ations in the activities of these enzymes were not re-
versed by dietary curcumin administration.
Sensitivity analysis
Studies that used the same model and course and simi-
lar dosages were included in the sensitivity analysis.18,19
Compared with the model group, the curcumin group
showed a reduction in urinary albumin excretion rate
[MD=0.80, 95% CI (0.50, 1.10), P<0.000 01, hetero-
geneity χ2=0.05, P=0.82, I2=0%] and lower blood sug-
ar levels [MD=1.65, 95% CI (0.40, 2.90), P=0.10, het-
erogeneity χ2=1.48, P=0.22, I2=33%] (Figures 12, 13).
Bias analysis
A funnel plot was drawn for 10 studies to compare uri-
nary protein levels between the curcumin group and
the model group.14,16-21,23,24,27 The results produced a
graph that was approximately symmetrical (Figure 14).
Elimination and death of animals during
experiments
The elimination of animals was reported in three stud-
ies and was because of unsuccessful models.14-16 Animal
deaths were reported in two studies.15,16 The total num-
ber of deaths was seven, but the reasons for the deaths
were not given. The average number of deaths at the
termination of experiments was described in nine stud-
ies, these being: anesthesia in six studies,15-19,26 euthana-
sia in one study,23 anddecapitation in two studies.20,21
Figure 10 Comparison of triglyceride levels between the model group and the curcumin group
Figure 11 Comparison of mesangial area to glomerular area ratios between the model group and the curcumin group
Figure 12 Sensitivity analysis of blood sugar levels between the model group and the curcumin group
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DISCUSSION
The current review found that, in addition to adverse
events and generalizability/translation, the other items
of the ARRIVE guidelines were reported in each of the
14 included studies. Compared with the normal
group, blood sugar levels and kidney weight to body
weight ratios were higher in the model group, which
suggested that DN models were successfully estab-
lished. These factors were similar to glomerular hyper-
filtration and changes of renal morphology in early hu-
man DN. When the model group was compared with
the curcumin group, many significant differences were
observed. For example, the curcumin group showed
lower blood sugar levels, a decreased intensity of
VEGF, and appeared to prevent reduction in AMPK
phosphorylation. Also, when taken together, data of
mesangial area to glomerular area ratios, kidney weight
to body weight ratios, urinary protein levels, BUN and
serum creatinine suggest the beneficial effects of cur-
cumin. For example, curcumin reduced mesangial area
to glomerular area ratios and kidney weight to body
weight ratios, and lowered the levels of urinary pro-
tein, BUN and serum creatinine. These outcomes may
be related to curcumin's regulation of blood sugar,
VEGF and AMPK. Additionally, sensitivity analysis in-
dicated that curcumin significantly lowered blood sug-
ar and urinary protein levels. No significant effects
were observed in the curcumin group with regard to
triglycerides, and aldose reductase and sorbitol dehy-
drogenase in renal tissues; however, this may be be-
cause of the small sample size and the different mod-
els. Further study is needed to fully elucidate the ef-
fects of triglycerides, and aldose reductase and sorbitol
dehydrogenase in renal tissues.
Curcumin has protective effects on the kidney in dia-
betic rats/mice. Further analysis using good quality
studies should be conducted to support our findings.
ACKNOWLEDGEMENTS
Special thanks to Prof. Li Saimei and Prof. Liu Min at
Guangzhou University of Traditional Chinese Medi-
cine for their guidance and support with this article.
REFERENCES
1 Furuichi K, Shimizu M, Toyama T, et al. Japan Diabetic
Nephropathy Cohort Study: study design, methods, and
implementation. Clin Exp Nephrol 2013; 17(6): 819-826.
2 Ayodele OE, Alebiosu CO, Salako BL. Diabetic nephrop-
athy-a review of the natural history, burden, risk factors
and treatment. J Natl Med Assoc 2004; 96(11):
1445-1454.
3 Folan LA, Tuttle KR. Diabetic nephropathy: implica-
tions for renal and cardiovascular outcomes. Minerva Med
2004; 95(5): 385-394.
4 Satirapoj B. Nephropathy in diabetes. Adv Exp Med Biol
2012; 771: 107-122.
5 Marshall SM. Recent advances in diabetic nephropathy.
Postgrad Med J 2004; 80(949): 624-633.
6 Peng WN, Luo R. The study of diabetic nephropathy. 1st
ed. Beijing: China Science and Technology Press, 2006:
2-3.
7 Lv RH, Zhao JX. Diagnosis and treatment of diabetes
and its complications with integrated traditional and west-
ern medicine. Beijing: People's Medical Publishng House,
2009: 590-591.
8 Zhou Y, Zheng Y, Ebersole J, Huang CF. Insulin secre-
tion stimulating effects of mogroside V and fruit extract of
Luo Han Kuo (Siraitia grosvenori Swingle) fruit extract.
Yao Xue Xue Bao 2009; 44(11): 1252−1257.
9 Li FL, Li QW, Geng GX, Li WY, Peng Y. Effects of poly-
saccharide of Portulaca oleracea L. on factors related to
glucose and lipid metabolism in diabetic mice. Xi Bei
Nong Lin Ke Ji Da Xue Xue Bao (Zi Ran Ke Xue Ban)
2012; 40(4): 15-20.
10 Zhou CJ, Huang MQ, Chen CQ, Lai XP, Qiu SQ. Salvi-
anolic Acid B Improves Glucose and Lipid Metabolism
and Insulin Resistance in Rat Models with Type 2 Diabe-
tes. Zhong Guo Shi Yan Fang Ji Xue Za Zhi 2012; 18
(13): 233-237.
11 Hooijmans CR, de Vries R, Leenaars M, Curfs J, Ritsk-
es-Hoitinga M. Improving planning, design, reporting
and scientific quality of animal experiments by using the
Figure 13 Sensitivity analysis of urinary albumin excretion rates between the model group and the curcumin group
Figure 14 Funnel plot of 10 studies examining urinary pro-
tein
SE (SMD)
SMD
0
1
2
3
4
5
-100 -50 0 50 100
24 h proteinuria 24 h albuminuria UAER
428
JTCM |www. journaltcm. com August 15, 2014 |Volume 34 | Issue 4 |
WuW et al. / Systematic Review
Gold Standard Publication Checklist, in addition to the
ARRIVE guidelines. Br J Pharmacol 2011; 162(6):
1259-1260.
12 Luo J, Leng WD. Theory & Practice of systematic review/
meta-analysis. Beijing: Press of Military Medical Sciences,
2013: 94-95.
13 Higgins JPT, Altman DG, Sterne JAC (editors) (2011)
Chapter 8: Assessing risk of bias in included studies. In:
Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1.0 (updat-
ed March 2011). The Cochrane Collaboration, 2011.
Available from www. cochrane-handbook. org.
14 Gao W, Zhang XM, Zhu LJ. Effect of curcumin on oxida-
tive stress in diabetic rats. Zhong Guo Shi Pin Tian Jia Ji
2013; 1: 88-91.
15 Sun CH, Zhang YL, Kong T, Li Y, Feng RN, Wang G.
Effects of curcumin intake on kidney and liver pathologi-
cal changes in T2DM rats. Wei Sheng Yan Jiu 2013; 42
(1): 6-9.
16 Yu DQ. The study of protective effect and mechanism of
curcumin on kidney of diabetic rats. Chongqing: Chongq-
ing Medical University, 2005: 1-88.
17 Xiong LJ. Effect of curcumin on diabetic nephropathy in
rats. Huazhong University of Science and Technology
2007: 1-23.
18 Huang YH. An experimental study of curcumin in Kid-
ney of streptozotocin-induced diabetic rats. Wuhan: Hua-
zhong University of Science and Technology 2006: 1-26.
19 Pan GW, Chen K, Ma YJ, Chen YG. Effect of Curcum in
on TNF-α, MCP-1 and Renal Function of Diabetic Ne-
phropathy Rats. Zhong Guo Zhong Yi Ji Zheng 2011; 20
(1): 98-99.
20 Su YJ, Hao CX, Huang GX, et al. The inhibitory efect of
curcumin on the upregulafion of PDGF-B expression in
the kidney of experimental diabetic rats. Hebei Yi Yao
2011; 33(2): 176-178.
21 Murugan P, Pari L. Influence of Tetrahydrocurcumin on
Hepatic and Renal Functional Markers and Protein Levels
in Experimental Type 2 Diabetic Rats. Basic Clin Pharma-
col Toxicol 2007; 101(4): 241-245.
22 Sawatpanich T, Petpiboolthai H, Punyarachun B, Anu-
punpisit V. Effect of curcumin on vascular endothelial
growth factor expression in diabetic mice kidney induced
by streptozotocin. J Med Assoc Thai 2010; 93(Suppl 2):
S1-S8.
23 Huang J, Huang KP, Lan T, et al. Curcumin ameliorates
diabetic nephropathy by inhibiting the activation 3 of the
SphK1-S1P signaling pathway. Mol Cell Endocrinol
2012; 365(2): 231-240.
24 Soetikno V, Sari FR, Sukumaran V, et al. Curcumin de-
creases renal triglyceride accumulation through AMPK–
SREBP signaling pathway in streptozotocin-induced type
1 diabetic rats. J Nutr Biochem 2012; 24(5): 796-802.
25 Tikoo K, Meena RL, Kabra DG, Gaikwad AB. Change in
post-translational modifications of histone H3, heat-shock
protein-27 and MAP kinase p38 expression by curcumin
in streptozotocin-induced type Ⅰ diabetic nephropathy.
Br J Pharmacol 2008; 153(6): 1225-1231.
26 Suresh BP, Srinivasan K. Amelioration of renal lesions as-
sociated with diabetes by dietary curcumin in streptozoto-
cin diabetic rats. Mol Cell Biochem 1998; 181(1-2):
87-96.
27 Lu MM. The effect of cureumin on diabetic nephropathy
in db/db mice. Changsha: Central South University,
2011: 1-45.
429
